The Adult-onset Still Disease market report also offers comprehensive insights into the Adult-onset Still Disease market size, share, Adult-onset Still Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Adult-onset Still Disease market size growth forward.
Some of the key highlights from the Adult-onset Still Disease Market Insights Report:
Several key pharmaceutical companies, including Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum, AB2 Bio Ltd., and others, are developing novel products to improve the Adult-onset Still Disease treatment outlook.
DelveInsight’s epidemiology model estimates that in the US, there were approximately 2,325 diagnosed prevalent cases of AOSD in 2023. This number is expected to increase during the forecast period (2024-2034), driven by greater awareness, improved screening, and advancements in genetic testing.
Among the EU4 countries and the UK, Germany had the highest number of diagnosed prevalent cases of AOSD, with about 691 cases in 2023. France followed with approximately 560 cases, and the UK had nearly 550 cases.
According to DelveInsight, in 2023, there were approximately 7,464 diagnosed cases of Adult-Onset Still’s Disease (AOSD) across the 7 Major Markets (7MM). The United States accounted for about 31% of these cases, while the EU4 and the UK collectively represented around 37%, and Japan accounted for nearly 32%.
The AOSD market is expected to grow steadily, with a projected compound annual growth rate (CAGR) of 5% from 2024 to 2034. This growth is driven by the introduction of new therapies, such as Tadekinig Alfa, along with increased awareness, improved diagnosis, and advancements in treatment options.
A key unmet need in AOSD treatment is the lack of personalized therapeutic strategies, as current treatments often show variable efficacy and adverse effects. This highlights the need for more tailored approaches.
FDA-approved drugs like Canakinumab (Novartis), Anakinra (Swedish Orphan Biopharma), and Tocilizumab (Roche) for AOSD indicate significant market potential, reflecting the growing recognition of AOSD as a distinct therapeutic target.
The total Adult-onset Still Disease market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
As per DelveInsight analysis, the Adult-onset Still Disease market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Adult-onset Still Disease Market Landscape
Adult-onset Still Disease Overview
Adult-Onset Still’s Disease (AOSD) is a rare systemic inflammatory condition with an unknown cause, leading to significant morbidity. It typically presents with a combination of symptoms such as high fever, a characteristic rash, prolonged joint pain, and systemic issues like sore throat, splenomegaly, hepatomegaly, and lymphadenopathy. While the exact causes are unclear, AOSD may be triggered by environmental factors or infections in individuals genetically predisposed to the condition. Risk factors include a history of autoimmune diseases and age, as AOSD primarily affects adults between their 20s and 40s. The complexity of its diagnosis and the variability of symptoms make treatment and management challenging, underscoring the need for increased awareness and further research.
Diagnosing AOSD requires a thorough clinical evaluation, including a detailed patient history and identification of characteristic symptoms. Since AOSD is mainly a diagnosis of exclusion, other inflammatory and autoimmune disorders must be ruled out. Diagnostic procedures typically involve blood tests showing specific changes, such as elevated white blood cell counts and anemia. The erythrocyte sedimentation rate (ESR) test is crucial for measuring systemic inflammation. Additional tests may include C-reactive protein (CRP) levels, liver function tests, and serological assessments for other autoimmune diseases. The diagnosis is made by combining clinical findings with laboratory results, highlighting the need for a systematic approach to accurately identify AOSD.
Do you know the treatment paradigms for different countries? Download our Adult-onset Still Disease Market Sample Report
Adult-onset Still Disease Epidemiology Segmentation
DelveInsight’s Adult-onset Still Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Adult-onset Still Disease historical patient pools and forecasted Adult-onset Still Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Adult-onset Still Disease Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
Adult-onset Still Disease Prevalence
Age-Specific Adult-onset Still Disease Prevalence
Gender-Specific Adult-onset Still Disease Prevalence
Diagnosed and Treatable Cases of Adult-onset Still Disease
Visit for more @ Adult-onset Still Disease Epidemiological Insights
Adult-onset Still Disease Market Outlook
Adult-Onset Still’s Disease (AOSD) is an autoinflammatory disorder driven by the innate immune system, presenting with symptoms such as fever, rash, arthritis, pharyngitis, and liver and spleen involvement. Due to its rarity and the absence of large-scale studies, diagnosing AOSD is challenging, and treatment often follows an empirical approach based on small retrospective case series.
First-line treatments for AOSD include NSAIDs and corticosteroids, but many patients fail to achieve remission with NSAIDs, prompting the use of disease-modifying antirheumatic drugs (DMARDs) and biologics when corticosteroids are ineffective. Biologic agents targeting inflammatory pathways, such as interleukin (IL) receptor antagonists and TNF inhibitors, have become key therapies. KINERET (anakinra), an IL-1 receptor antagonist, is commonly prescribed for refractory cases, while ILARIS (canakinumab) has also been approved for AOSD, marking a significant therapeutic advancement. In Japan, ACTEMRA (tocilizumab), an anti-IL-6 receptor monoclonal antibody, is approved for patients who do not respond to other treatments.
Emerging treatments for AOSD include Tadekinig alfa, a recombinant IL-18 Binding Protein developed by AB2 Bio, which showed promise in early Phase II trials. However, limited recent data on its efficacy prevents its inclusion in future forecasts. Overall, the treatment landscape for AOSD is evolving, with ongoing research aimed at improving therapeutic options for patients.
Adult-onset Still Disease Marketed Drugs
ILARIS (canakinumab): NOVARTIS
KINERET (anakinra): Swedish Orphan Biovitrum
ACTEMRA (tocilizumab): Genentech (ROCHE)
Adult-onset Still Disease Emerging Drugs
Tadekinig Alfa: AB2 Bio
Adult-onset Still Disease Key Companies
Cerecor
Roche
Swedish Orphan Biovitrum
Novartis
AB2 Bio Ltd.
And others
For more information, visit Adult-onset Still Disease Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Adult-onset Still Disease Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Adult-onset Still Disease, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Adult-onset Still Disease epidemiology in the 7MM
Adult-onset Still Disease marketed and emerging therapies
Adult-onset Still Disease companies
Adult-onset Still Disease market drivers and barriers
Table of Contents:
1 Adult-onset Still Disease Market Key Comprehensive Insights
2 Adult-onset Still Disease Market Report Introduction
3 Competitive Intelligence Analysis for Adult-onset Still Disease
4 Adult-onset Still Disease Market Analysis Overview at a Glance
5 Executive Summary of Adult-onset Still Disease
6 Adult-onset Still Disease Epidemiology and Market Methodology
7 Adult-onset Still Disease Epidemiology and Patient Population
8 Adult-onset Still Disease Patient Journey
9 Adult-onset Still Disease Treatment Algorithm, Adult-onset Still Disease Current Treatment, and Medical Practices
10 Key Endpoints in Adult-onset Still Disease Clinical Trials
11 Adult-onset Still Disease Marketed Therapies
12 Adult-onset Still Disease Emerging Therapies
13 Adult-onset Still Disease: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Adult-onset Still Disease
16 Adult-onset Still Disease Market Key Opinion Leaders Reviews
18 Adult-onset Still Disease Market Drivers
19 Adult-onset Still Disease Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Adult-onset Still Disease Epidemiology 2034
DelveInsight’s “Adult-onset Still Disease – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Adult-onset Still Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Adult-onset Still Disease Pipeline 2024
“Adult-onset Still Disease Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Adult-onset Still Disease market. A detailed picture of the Adult-onset Still Disease pipeline landscape is provided, which includes the disease overview and Adult-onset Still Disease treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
